ArticleGene therapy2007
Inhibition of HIV-1 replication with designed miRNAs expressed from RNA polymerase II promoters.
Article in Gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Gamma-retrovirus design for efficacious microRNA-mediated gene knock-down and protein co-expression without compromising titers.NAR molecular medicine · 2025Article
- A Small Molecule-Controlled Cas9 Repressible System.Molecular therapy. Nucleic acids · 2020Article
- Efficient inhibition of human immunodeficiency virus replication using novel modified microRNA-30a targeting 3'-untranslated region transcripts.Experimental and therapeutic medicine · 2016Article
- Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations.Molecular therapy. Nucleic acids · 2016Article
- Stem cell transplantation in strategies for curing HIV/AIDS.AIDS research and therapy · 2016Review
- Multiplexing seven miRNA-Based shRNAs to suppress HIV replication.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Gamma-retroviral vector design for the co-expression of artificial microRNAs and therapeutic proteins.Nucleic acid therapeutics · 2014Article
- Efficient inhibition of HIV-1 replication by an artificial polycistronic miRNA construct.Virology journal · 2012Article
- ACVR1, a therapeutic target of fibrodysplasia ossificans progressiva, is negatively regulated by miR-148a.International journal of molecular sciences · 2012Article
- MicroRNAs in HIV-1 infection: an integration of viral and cellular interaction at the genomic level.Frontiers in microbiology · 2012Article
- Stem cell-based anti-HIV gene therapy.Virology · 2011Review
- Article
- RNAi-mediated inhibition of HIV-1 by targeting partially complementary viral sequences.Nucleic acids research · 2009Article
- Lentiviral delivery of short hairpin RNAs.Advanced drug delivery reviews · 2009Review
- Oncoviruses and Pathogenic MicroRNAs in Humans.The open virology journal · 2009Article
- International progress in cancer gene therapy.Cancer gene therapy · 2008Review
- MicroRNA: An emerging therapeutic target and intervention tool.International journal of molecular sciences · 2008Article
- Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron.Nucleic acids research · 2008Article
- Concise review: MicroRNA expression in multipotent mesenchymal stromal cells.Stem cells (Dayton, Ohio) · 2008Review
- RNA interference against viruses: strike and counterstrike.Nature biotechnology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Small interfering RNA (siRNA) mediates sequence-specific RNA cleavage and represents a potential approach to treat the infection of human immunodeficiency virus (HIV). Expression of a single siRNA species frequently led to the emergence of HIV escape variants. Thus, multiple siRNAs targeted to different regions in the HIV-1 genome may be required. However, overexpression of different anti-HIV siRNA genes from multiple pol III promoters can induce cell toxicity, thus may not be a viable option in the setting of human gene therapy trials. In the current study, we evaluated the strategy of using pol II promoters to drive the expression of siRNAs against HIV-1. We replaced the stem sequence in the stem-loop structure of the well-characterized miR-30a with siRNA sequences and showed that designed microRNA (miRNA) could be expressed from pol II promoters. We demonstrated efficient inhibition of HIV-1 replication with such designed miRNA, but the efficacy was directly correlated with the expression level. Both the vector copy number and the promoter strength directly affected the ability of the siRNA to inhibit HIV-1 replication. We also showed that a combination of pol II and pol III promoters to express two different siRNAs increased the efficacy against HIV-1 replication without comprising cell viability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.